found that GLP-1 RAs are associated with an increased risk of gallbladder and biliary diseases (including cholelithiasis and cholecystitis), particularly at higher doses, longer treatment durations, and when used for weight loss [129]
This question typically arises due to cost concerns, supply shortages, or injection fatigue
But persistent diarrhea, severe weakness, dizziness, or inability to keep fluids down should be discussed with a healthcare provider
Next week I'm back on and this is a stack that I'm resuming with
Once your order has been received and processed, we will forward the tracking information to the email linked to your patient portal
High-density lipoprotein in lupus: disease biomarkers and potential therapeutic strategy